Clinical Trial Update: Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating panobinostat with everolimus in recurrent hematologic malignancies including multiple myeloma and non-Hodgkin lymphomas; completed wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• Everolimus (everolimus)
• Panobinostat (Panobinostat)

Snippet

Sponsor: Mayo Clinic | Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-05-18